NCT01465152 - Comparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 Diabetes | Biotech Hunter

Enrollment

182

Participants

Timeline

Start Date

March 6, 2002

Primary Completion Date

October 21, 2004

Study Completion Date

October 21, 2004

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

metformin

Adminstered orally during the three main meals for 24 weeks

DRUG

repaglinide

Administered orally before the three main meals for 24 weeks

Trial Locations (18)

18012

Novo Nordisk Investigational Site, Granada

27004

Novo Nordisk Investigational Site, Lugo

28021

Novo Nordisk Investigational Site, Madrid

28030

Novo Nordisk Investigational Site, Madrid

28035

Novo Nordisk Investigational Site, Madrid

28942

Novo Nordisk Investigational Site, Fuenlabrada

29718

Novo Nordisk Investigational Site, Benamargosa

31600

Novo Nordisk Investigational Site, Burlata

33212

Novo Nordisk Investigational Site, Gijón

38280

Novo Nordisk Investigational Site, Tegueste

39009

Novo Nordisk Investigational Site, Santander

39011

Novo Nordisk Investigational Site, Santander

41900

Novo Nordisk Investigational Site, Camas

46021

Novo Nordisk Investigational Site, Valencia

48920

Novo Nordisk Investigational Site, Portugalete

50007

Novo Nordisk Investigational Site, Zaragoza

08020

Novo Nordisk Investigational Site, Barcelona

08930

Novo Nordisk Investigational Site, San Adria Del Besos